About Ensysce
Ensysce is a company based in Houston (United States) founded in 2008.. Ensysce has raised $2.5 million across 9 funding rounds from investors including HHS, SBIR and Texas Emerging Technology Fund. The company has 9 employees as of December 31, 2024. Ensysce has completed 1 acquisition, including Signature Therapeutics. Ensysce offers products and services including TAAP™ and MPAR®. Ensysce operates in a competitive market with competitors including PharmaJet, Arecor, Suono Bio, Renovis and Splice Bio, among others.
- Headquarter Houston, United States
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ensysce Biosciences, Inc.
-
Annual Revenue
$5.21 M133.58as on Dec 31, 2024
-
Net Profit
$-7.99 M24.74as on Dec 31, 2024
-
EBITDA
$-6.73 M37.21as on Dec 31, 2024
-
Total Equity Funding
$2.5 M (USD)
in 9 rounds
-
Latest Funding Round
$4 M (USD), Post-IPO
Nov 17, 2025
-
Investors
HHS
& 2 more
-
Employee Count
9
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ensysce
Ensysce is a publicly listed company on the NASDAQ with ticker symbol ENSC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ensysce
Ensysce offers a comprehensive portfolio of products and services, including TAAP™ and MPAR®. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Reduces drug abuse risks through novel platform for oral prescriptions
Prevents opioid overdose with multi-pill resistant features
Unlock access to complete
Unlock access to complete
Funding Insights of Ensysce
Ensysce has successfully raised a total of $2.5M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $4.0M
-
First Round
First Round
(14 Jun 2010)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Post-IPO - Ensysce | Valuation |
investors |
|
| Feb, 2023 | Amount | Post-IPO - Ensysce | Valuation |
investors |
|
| Jun, 2022 | Amount | Post-IPO - Ensysce | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ensysce
Ensysce has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, SBIR and Texas Emerging Technology Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Federal innovation and scientific achievement services are provided.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ensysce
Ensysce has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Signature Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Prodrug formulations are developed to prevent prescription medication misuse.
|
2004 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ensysce
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ensysce Comparisons
Competitors of Ensysce
Ensysce operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PharmaJet, Arecor, Suono Bio, Renovis and Splice Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of needle-free injection technology
|
|
| domain | founded_year | HQ Location |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| domain | founded_year | HQ Location |
Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract
|
|
| domain | founded_year | HQ Location |
Drugs for neurological diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Provider of a proprietary platform for gene therapy
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ensysce
Frequently Asked Questions about Ensysce
When was Ensysce founded?
Ensysce was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Where is Ensysce located?
Ensysce is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
Who is the current CEO of Ensysce?
Lynn Kirkpatrick is the current CEO of Ensysce.
Is Ensysce a funded company?
Ensysce is a funded company, having raised a total of $2.5M across 9 funding rounds to date. The company's 1st funding round was a Post-IPO of $8M, raised on Jun 14, 2010.
How many employees does Ensysce have?
As of Dec 31, 2024, the latest employee count at Ensysce is 9.
What is the annual revenue of Ensysce?
Annual revenue of Ensysce is $5.21M as on Dec 31, 2024.
What does Ensysce do?
Ensysce was founded in 2008 and is based in Houston, United States. Operations focus on the biotechnology sector, where single-walled carbon nanotubes are developed for cancer treatment applications. These nanotubes enable delivery of active agents, including small interfering RNA, cancer drugs, and alpha-emitting radiation, into tumor cells while bypassing natural barriers and minimizing exposure to healthy tissues.
Who are the top competitors of Ensysce?
Ensysce's top competitors include Oxular, PharmaJet and Splice Bio.
What products or services does Ensysce offer?
Ensysce offers TAAP™ and MPAR®.
Is Ensysce publicly traded?
Yes, Ensysce is publicly traded on NASDAQ under the ticker symbol ENSC.
How many acquisitions has Ensysce made?
Ensysce has made 1 acquisition, including Signature Therapeutics.
Who are Ensysce's investors?
What is Ensysce's ticker symbol?
The ticker symbol of Ensysce is ENSC on NASDAQ.